Format

Send to

Choose Destination
See comment in PubMed Commons below
J Inorg Biochem. 2013 Oct;127:79-81. doi: 10.1016/j.jinorgbio.2013.07.002. Epub 2013 Jul 12.

First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.

Author information

1
Centro de Ciências Moleculares e Materiais, Departamento de Química e Bioquímica Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal. Electronic address: amvalente@fc.ul.pt.

Abstract

d-glucose end-capped polylactide ruthenium cyclopentadienyl complex (RuPMC) was newly synthesized by a straightforward method. RuPMC was tested against human MCF7 and MDAMB231 breast and A2780 ovarian adenocarcinoma revealing IC50 values in the micromolar range. A pH dependent hydrolysis is advanced by preliminary UV-visible spectroscopy. Cellular distribution studies showed that RuPMC is predominantly found in the nucleus and in the membrane. Data suggest potential application of RuPMC as a new drug delivery system for Ru(II)Cp compounds.

KEYWORDS:

Anticancer agent; Drug delivery; Polylactide; Ruthenium cyclopentadienyl

PMID:
23896008
DOI:
10.1016/j.jinorgbio.2013.07.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center